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The major cause of late death in cardiac transplant recipients is cardiac allograft vascu-
lopathy, also referred to as cardiac transplant atherosclerosis, which occurs in as many
as 45% of transplant recipients who survive longer than 1 year. It differs from typical
atherosclerosis in that intimal hyperplasia is concentric and diffuse, the internal elastic
lamina remains intact, calcification is rare, and the disease tends to develop rapidly.
Intravascular ultrasound and coronary angioscopy are more sensitive diagnostic mea-
sures of cardiac allograft vasculopathy than is coronary angiography. Although re-
transplantation at present seems to be the only definitive therapy for cardiac allograft
vasculopathy, it has shown only fair results. Recent studies have suggested that cal-
cium entry blockers and angiotensin-converting enzyme inhibitors may play a beneficial
role in delaying the progression of cardiac allograft vasculopathy. (Tex Heart Inst J 1995;
22:138-44)
A dvances in immunosuppression and improved recipient selection have
resulted in an increased survival of cardiac allograft recipients, with
1-year survival rates approaching 85%.1-3 Despite this improvement in
patient survival, the most common cause of late death is cardiac allograft vascu-
lopathy, a unique and unusually accelerated form of coronary artery disease. Early
experiments with canine cardiac transplantation in the late 1960s by Kosek and
colleagueS4s 1st reported this phenomenon, and its occurrence in human cardiac
allografts was subsequently verified by Thomson6 and by Bieber's group. Car-
diac allograft vasculopathy is angiographically evident in as many as 45% of heart
transplant recipients who survive 3 or more years;8 and these patients have a 5-
fold greater relative risk of developing other cardiac events, such as myocardial
infarction, terminal heart failure, and sudden death.8
This report reviews the current concepts in the diagnosis and management of
cardiac allograft vasculopathy, with specific consideration of the pathologic char-
acteristics, diagnosis, and treatment of the disease.
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Several histopathologic studies by Billinghamr"" have established the diffuse na-
ture of cardiac allograft vasculopathy, which affects the major epicardial vessels
along their entire length from the base of the heart to the apex and the epicardial
and intramyocardial branches. In fact, this disease is not limited to the coronary
vasculature, for it has been demonstrated to involve the venous structures" and
the great vessels within the cardiac allograft.'2 The classic allograft lesion consists
of progressive concentric myointimal proliferation that appears as intimal thick-
ening and ultimately results in luminal occlusion.'0
There are several differences between this condition and the more commonly
seen native atherosclerosis (Table I). The latter demonstrates eccentric, focal, and
proximal lesions of major epicardial coronary arteries.9 These lesions contain
calcium, disrupt the internal elastic lamina, and develop over many years. Con-
versely, cardiac allograft vasculopathy is associated with concentric, diffuse, and
distal lesions of the coronary vessels and branches. The internal elastic lamina is
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TABLE 1. Histopathologic Findings in Cardiac Allograft
Vasculopathy and Coronary Artery Disease
Factors under
Comparison
Localization
Intimal proliferation
Internal elastic lamina
Vasculitis
Calcium deposit
Rate of development
Cardiac Allograft
Vasculopathy:
Findings
Coronary Artery
Disease: Findings
Diffuse, distal Focal, proximal
Concentric
Intact
Infrequent
Absent
Months
Eccentric
Disrupted
Never
Present
Years
intact, calcification is rare, a low grade of vasculitis
is occasionally present, and the disease tends to de-
velop rapidly.9"10
Histopathologic studies, however, have demon-
strated that more typical focal and complicated ath-
erosclerotic plaques may also be present in older
cardiac allografts, indicating that cardiac allograft
vasculopathy has a spectrum of pathologic features.
Thus, it has been demonstrated that early intimal
proliferation progresses after transplantation, as sub-
sequent increases in lipid deposits and calcification
occur in the coronary vessels.'3 Over time, these
more typical atherosclerotic processes are likely su-
perimposed upon the cardiac allograft.
Diagnosis
Clinical Symptoms
To rely on the presentation of clinical symptoms for
the diagnosis of cardiac allograft vasculopathy can
be perilous, since the lack of afferent autonomic in-
nervation results in the inability of most allograft
recipients to experience angina pectoris. Although
partial restoration of the allograft's nerve supply
occurs in up to one third of heart transplant recipi-
ents who survive at least 1 year, cardiac allograft
vasculopathy rarely presents with angina. Therefore,
silent myocardial infarction, heart failure with the
loss of allograft function, and sudden death are its
most common forms of presentation.8
Noninvasive Diagnosis
Noninvasive studies routinely used to diagnose con-
ventional coronary artery disease have not been
found to be useful in diagnosing cardiac allograft
vasculopathy.
A study by Smart and coworkers'4 assessed the
use of several noninvasive tests for detecting allo-
graft vasculopathy in 73 cardiac transplant recipients
who were followed prospectively for an average
duration of 2.5 years. Patients underwent an annu-
al follow-up examination, including 2-dimensional
echocardiography, supine rest and bicycle exercise-
gated wall-motion study, 48-hour Holter recording,
oral dipyridamole thallium-201 SPECT (single pho-
ton emission computed tomographic) imaging, and
coronary angiography. In regard to the presence of
arrhythmia, ambulatory electrocardiographic moni-
toring detected significant differences between the
groups with and without cardiac allograft vascu-
lopathy. The sensitivity and specificity of dipyri-
damole thallium-201 SPECT imaging were 21% and
80%, respectively, comparable with a sensitivity and
specificity for supine bicycle exercise radionuclide
angiography of 21% and 77%, respectively. The in-
ability of noninvasive studies to detect differences
in myocardial uptake or redistribution may ensue
from the diffuse nature of the disease.
Invasive Diagnosis
Coronary Angiography. Both the patient's inabil-
ity to experience angina pectoris and the poor pre-
dictive value of noninvasive tests have led to the
establishment of annual surveillance angiography as
the primary method used to detect and follow the
development of cardiac allograft vasculopathy.
A grading system has been developed by Gao and
associates"' for the standard definition of coronary
lesions on the basis of angiographic appearance.
Lesions can be classified as Type A, B, or C. Type A
lesions are discrete and tubular stenoses of the prox-
imal epicardial vessels; Type B lesions are character-
ized by diffuse concentric narrowing of the middle
or distal coronary vessels and can be subclassified
into Type Bi lesions (indicating an abrupt narrow-
ing) or B2 lesions (indicating smooth concentric ta-
pering); Type C lesions are characterized by distal
narrowing and irregularities and by loss of small
branches.'5 In patients with cardiac allograft vascu-
lopathy, angiographic Type Bi, B2, and C lesions are
more commonly found, whereas Type A lesions are
seen only rarely. Conversely, in patients with typical
coronary atherosclerosis, Type A lesions predomi-
nate and Type Bi, B2, and C lesions are almost never
seen.'5 Although coronary angiography may have a
high specificity in diagnosing cardiac allograft vas-
culopathy, it has been shown to underestimate the
presence of disease and, therefore, has not proved
to be a sensitive method. The insensitivity of coro-
nary angiography in diagnosing cardiac allograft
vasculopathy has been demonstrated both by histo-
pathologic studiesl6l8 and by comparison with intra-
vascular ultrasound diagnosis.'9 In 1 histopathologic
study of 10 failed human allografts, Johnson and
associates'7 showed the presence of significant inti-
mal hyperplasia in 75% of angiographically normal
coronary segments. Quantitative coronary angiog-
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raphy, performed either manually or by automated
video densitometry, may improve the estimation of
coronary narrowing. It may, therefore, be a more
sensitive method of diagnosing cardiac allograft vas-
culopathy.20
Other Coronary Artery Imaging Techniques. Cor-
onary angioscopy and intravascular ultrasonog-
raphy, 2 novel intracoronary imaging methods, have
been used recently in heart transplant recipients to
evaluate the morphology of cardiac allograft vas-
culopathy. These methods have proved to be more
sensitive than coronary angiography and have al-
lowed more precise evaluation of the morphologic
characteristics of the atherosclerotic plaque and the
structure of the vessel wall.21-24 In a recent histologic
study, Siegel's group25 validated the images obtained
by these techniques, demonstrating a high concor-
dance with histologic classification.
CoronaryAngioscopy. Studies from our institution
indicate that coronary angioscopy is more sensitive
than coronary angiography for detecting cardiac al-
lograft vasculopathy.2' The 1st study consisted of 37
cardiac transplant recipients who underwent coro-
nary angioscopy with a steerable microangioscope
at the time of the annual coronary angiography.
When the 2 methods were compared, only 13% of
the coronary sites were abnormal by quantitative
coronary angiography, whereas 84% of the sites
were abnormal by coronary angioscopy (p=0.005).
The abnormalities seen by coronary angioscopy
were pigmented (yellow) or nonpigmented (white)
plaque, with or without coronary stenosis.
In a 2nd study, 20 cardiac transplant recipients
underwent coronary angioscopy at baseline and an-
nually thereafter.22 Angioscopic findings were classi-
fied as: Normal; Grade 1, pigmented yellow or white
plaque without stenosis; Grade 2, <50% stenosis; or
Grade 3, .50% stenosis. Normal or Grade 1 angio-
scopic findings were prevalent 1 to 2 years after
cardiac transplantation, whereas Grade 2 or 3 angio-
scopic findings were prevalent 3 to 5 years after
transplantation.
Angioscopic findings in native coronary athero-
sclerosis appear as a yellow plaque, owing to lipid
deposits, and lesions of restenosis after balloon di-
lation are seen as a white plaque that results from
smooth muscle cell proliferation and fibrosis.26
Therefore, in heart transplant recipients, those le-
sions that appear pigmented (Fig. 1) likely contain
lipid deposits, whereas nonpigmented lesions (Fig.
2) are due to myointimal proliferation and fibrosis.
Further long-term studies are needed to delineate
the clinical use of coronary angioscopy in diagnos-
ing cardiac allograft vasculopathy.
Intravascular Ultrasound. Intravascular ultra-
sound has now emerged as a safe clinical tool for
the early diagnosis of cardiac allograft vasculopathy
Fig. 1 Yellow plaque. Left panel: Angiographic views of the
right coronary artery at 3 years (A) and 4 years (B). Right
panel: Corresponding angioscopic appearance demonstrating
yellow plaque.
I
B
Fig. 2 White plaque. Left panel: Angiographic views of the
left anterior descending artery at 1 year (A) and 2 years (B).
Right panel: Corresponding angioscopic appearance demon-
strating white plaque.
that provides accurate quantitative information
about vessel wall thickness and morphology, and
about luminal dimensions in vivo (Fig. 3). Further-
more, intravascular ultrasound enables a more
sensitive assessment of calcification than either
angiography or angioscopy.22
Intimal thickening resulting from myointimal
hyperplasia is the hallmark of cardiac allograft vascu-
lopathy and can be detected early by intravascular
ultrasound. Fitzgerald and colleagues27 demon-
strated that intravascular ultrasound can detect in-
timal thickening of as little as 178 jum. While the
intracoronary ultrasound appearance of normal
coronary artery walls is homogenous and without
evidence of layering, a 3-layered appearance is ab-
normal and associated with intimal hyperplasia. Sev-
eral studies from our institution22'28 and others'9 have
shown that intravascular ultrasound is more sensi-
tive than coronary angiography for diagnosing car-
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Fig. 3 Measurement of plaque area by intravascular ultra-
sound.
IA = intimal area; 11 = intimal index; LA = lumen area;
TA = total area
diac allograft vasculopathy. We have found that 80%
of coronary segments in cardiac transplant recipients
manifested intimal thickening by intravascular ultra-
sound, although only 10% of these were evident on
routine angiography.28 St. Goar and co-authors19 have
established a useful grading classification of ultra-
sound findings in heart transplant recipients: Class
0, no measurable intimal layer; Class I (minimal), an
intimal layer <0.3 mm of the vascular circumference;
Class II (mild), an intimal layer <0.3 mm but mea-
surable in >1800 of the vascular circumference; Class
III (moderate), an intimal layer 0.3 to 0.5 mm thick,
or an intimal layer >0.5 mm thick involving <180° of
the vascular circumference; and Class IV (severe),
>0.5 mm intimal thickening involving >1800 of the
vascular circumference or an intimal layer >1.0 mm
in any 1 area of the vascular circumference.'9
The introduction of instruments into vessels raises
the concern that catheter-induced vascular wall dam-
age may accelerate the proliferative process, espe-
cially in arteries that have no apparent disease. In a
study that analyzed 170 cardiac transplant patients
who underwent 240 intracoronary studies, no clini-
cal morbidity was seen. In addition, there was a low
incidence of vascular spasm, and no evidence of ac-
celerated progression of disease was noted. There-
fore, intravascular ultrasound can be used safely in
vessels not undergoing therapeutic intervention.29
In addition to delineating morphologic character-
istics, intravascular ultrasound affords an opportu-
nity to assess the transplanted vessel's responses to
pharmacologic stimuli. It has been shown that the
vessel's vasodilatory response to nitroglycerin is at-
tenuated during episodes of acute rejection, and is
independent of the degree of intimal thickening.30
Furthermore, Heroux and colleagues31 have dem-
onstrated that combining data on the vascular re-
sponses of endothelium-dependent vasodilators with
data on vessel wall morphology is useful for detect-
ing the presence of cardiac allograft vasculopathy.
The functional significance of intimal thickening
was evaluated in a study by Anderson and cowork-
ers32 that showed that intimal thickening begins as a
heterogenous process and increases in extent over
time. This study also demonstrated that endothelial
dysfunction occurs before the appearance of inti-
mal thickening. Furthermore, we and others3-35 have
shown that intimal hyperplasia progresses as time
passes after transplantation. The excellent reproduc-
ibility of measurements of luminal and intimal areas
by intravascular ultrasound suggests that this tech-
nique can also be used serially, to characterize the
rate of progression of disease and to evaluate the
effects of putative risk factors and therapeutic inter-
ventions (Fig. 4).
In addition, intimal hyperplasia can predict clin-
ical outcome in cardiac transplant recipients. In a
study that used intravascular ultrasound to evaluate
74 consecutive heart transplant patients,-j6 the find-
ing of severe concentric intimal thickening (>0.5
mm) identified a group of patients at high risk for
cardiovascular events, including sudden death, myo-
cardial infarction, and need for revascularization
(Fig. 5).
Treatment
Prevention
Although cardiac allograft vasculopathy is thought to
be an immunologic disease, advances in immuno-
suppression have not decreased its incidence.37
However, prevention remains the primary goal of
most centers in their approach to cardiac allograft
vasculopathy.
Risk Factor Modification
Most heart transplant centers encourage risk factor
modification in the hope that the expression of car-
diac allograft vasculopathy can at least be delayed.
Although hyperlipidemia and obesity are positively
correlated with the occurrence of cardiac allograft
vasculopathy, no studies have demonstrated conclu-
sively the beneficial impact of lipid lowering or
weight loss on this disease. Moreover, treatment of
post-transplant hypertension has not been demon-
strated to reduce the development of cardiac allo-
graft vasculopathy.
Pharmacologic Interventions
Since platelets are an integral constituent of endo-
thelial injury in immune and nonimmune vascular
damage, there is an intuitive logic in using platelet-
modifying agents. However, studies with initially
encouraging reports of the efficacy of aspirin, di-
pyridamole, and warfarin in small groups of patients
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Fig. 4 Progression of intimal hyperplasia despite a normal
angiogram. Left panel: Angiographic views of the left anterior
descending artery at 1 year (A) and 3 years (B) after transplan-
tation. Right panel: Corresponding ultrasound images
demonstrating a significant increase in intimal thickening.
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Fig. 5 The degree of intimal hyperplasia as indicated by
intravascular ultrasound predicts cardiac events.
have yielded rather disappointing results at follow-
up." Although the use of dipyridamole has beer
largely abandoned, some transplant centers still rou-
tinely use platelet-active agents, such as aspirin, ir
heart transplant recipients.
Using quantitative angiography, Schroeder anc
associates39 have suggested that calcium entry block
ers, specifically diltiazem, may delay the progressior
of cardiac allograft vasculopathy and may also resul
in regression of these lesions. Using intravascula]
ultrasound, we have recently shown that heart trans
plant recipients, treated with either calcium entr~
blockers or angiotensin-converting enzyme inhibi
tors, have a significantly lesser degree of intima
hyperplasia at 1 year after cardiac transplantatior
than do matched, untreated control patients.4" Long
er follow-up studies with larger numbers of patientv
are needed to confirm these findings (Fig. 6). Ani
mal studies evaluating the role of dehydroepian
drosterone,41 omega-3 fatty acids,42 or angiopeptin4
E 0.6-
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Fig. 6 Intimal hyperplasia as detected by intravascular ultra-
sound at the end of the 1st postoperative year, in heart trans-
plant recipients treated with angiotensin-converting enzyme
inhibitors (ACE 1), calcium entry blockers (CEB), or both.
have suggested that these agents may retard the dis-
ease. However, this has not been conclusively dem-
onstrated in human cardiac transplant recipients.
Percutaneous Interventions
A recent multicenter study has shown that percu-
taneous transluminal coronary angioplasty can be
performed in cardiac allograft vasculopathy with a
morbidity and short-term success similar to those in
native atherosclerosis.44 Coronary angioplasty45 and
atherectomy46 have been performed successfully for
discrete proximal stenoses. Therefore, the goals of
percutaneous interventions in cardiac transplant re-
cipients are to reduce the occurrence of clinically
silent morbid events and to prolong allograft func-
tion in patients awaiting repeat transplantation.
Repeat Transplantation
Currently, retransplantation is the only definitive
therapy for severe cardiac allograft vasculopathy.
However, the survival rates for retransplantation are
significantly lower than those for primary heart
transplantation (1-year survival, 50% versus 80%, re-
spectively).4748
Conclusion
A
t
r
I
~3
There is an urgent need to investigate the effective-
ness of pharmacologic therapy in heart transplant
patients by using more sensitive and precise imag-
ing techniques, such as intravascular ultrasound and
intracoronary angioscopy. Unless therapeutic ad-
vances are made, the long-term success of cardiac
transplantation will remain in jeopardy.
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